Refine Search
(0)
(1)
(1)
(3)

Type 2 Diabetes - 'Me-too' Drugs

Despite the growing number of candidates in the T2D pipeline, KOLs interviewed by GlobalData have repeatedly communicated that pipeline ‘me-too’ T2D drugs fall short of meeting one of the most pressing unmet needs in the space: sustained glycemic control, with a focus on decreasing insulin resistance and preserving β-cell function. As such, KOLs have largely shifted their sights from the ‘me-too’ populated late-stage pipeline to the early-stage pipeline in the hopes that novel treatments will help address the aforementioned unmet need.

Type 2 Diabetes: Competitive Landscape to 2026

  • $3,495
  • March 2018
Add to Basket Quick View Add to Saved List

Type 2 Diabetes (T2D) is a chronic disease characterized by insulin resistance and pancreatic β-cell failure, with an underlying genetic predisposition heavily influenced by diet and lifestyle. Insulin is a hormone that regulates the glucose le...

PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2026

  • $10,995
  • July 2017
Add to Basket Quick View Add to Saved List

While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, GlobalData expects this market to undergo substantial growth between 2016 and 2026, doubling over the forecast period. The main ...

Opportunity Analyzer: Diabetic Foot Ulcers – Opportunity Analysis and Forecast to 2025

  • $10,995
  • December 2016
Add to Basket Quick View Add to Saved List

GlobalData estimates sales of diabetic foot ulcer (DFU) and diabetic foot infection (DFI) drugs to be approximately $292.1M across the 7MM in 2015, encompassing the US, 5EU, and Japan. DFU sales alone accounting for $118.7M across the 7MM. The ...

PharmaPoint: Type 1 Diabetes – Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • March 2015
Add to Basket Quick View Add to Saved List

Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at ...